AMAG Pharmaceuticals, Inc. Shares Fall Drug Approval Concerns
NEW YORK (Associated Press) - Shares of biopharmaceutical company AMAG Pharmaceuticals Inc. fell Friday on investor concern over the company's iron deficiency treatment and auction rate securities. Additionally, the company on Thursday reported worse results than Wall Street expected. Nevertheless, analysts remained positive on the stock.